4-Aminosalicylic acid
Based on 1 publication(s) in Google Scholar
4-Aminosalicylic acid is an inhibitor for dihydrofolate reductase (DHFR) and an antituberculous agent. 4-Aminosalicylic acid exhibits anti-inflammatory activity and can be used in research of inflammatory bowel disease (IBD). 4-Aminosalicylic acid is orally active.
For research use only. We do not sell to patients.
- Purity: 99.82%
- CAS No.: 65-49-6
- Formula: C7H7NO3
- Molecular Weight:153.14
-
Storage:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Antibacterial Compound Library
HY-L049
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
Human Metabolite Library
HY-L123
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Off-patent Drug Library
HY-L141
-
Anti-tuberculosis Compound Library
HY-L142
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) 4-Aminosalicylic acid
MoreAll Antibiotic Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
>1270 μM
Compound: PAS
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability
Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability
|
[PMID: 37423128] |
| HepG2 | IC50 |
2240 μM
Compound: PAS
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay
|
[PMID: 24953953] |
| HepG2 | IC50 |
2240 μM
Compound: PAS
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 25593095] |
| HepG2 | IC50 |
2240 μM
Compound: PAS
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after overnight incubation by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after overnight incubation by MTT assay
|
[PMID: 31401536] |
4-Aminosalicylic acid is incorporated into the folate pathway via dihydropteroate synthase (DHPS) and dihydrofolate synthase (DHFS) to generate the hydroxydihydrofolate antimetabolite, which in turn inhibits DHFR enzyme activity[1].
4-Aminosalicylic acid inhibits M. tuberculosis H37Rv growth with MIC value of 0.4 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 65-49-6
-
Appearance Solid
-
Molecular Weight 153.14
-
Formula C7H7NO3
-
Color Off-white to light brown
-
SMILES
O=C(O)C1=CC=C(N)C=C1O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 Jul;643(8070):192-200. PMID: 39695227
Solvent & Solubility
DMSO : 100 mg/mL (653.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (16.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (16.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zheng J, et al. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem. 2013 Aug 9;288(32):23447-56. [Content Brief]
[2]. Abdu-Allah HHM, et al. Conjugation of 4-aminosalicylate with thiazolinones afforded non-cytotoxic potent in vitro and in vivo anti-inflammatory hybrids. Bioorg Chem. 2020 Jan;94:103378. [Content Brief]
[3]. Dhaneshwar SS. Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease. World J Gastroenterol. 2014 Apr 7;20(13):3564-71. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.5300 mL | 32.6499 mL | 65.2997 mL | 163.2493 mL |
| 5 mM | 1.3060 mL | 6.5300 mL | 13.0599 mL | 32.6499 mL | |
| 10 mM | 0.6530 mL | 3.2650 mL | 6.5300 mL | 16.3249 mL | |
| 15 mM | 0.4353 mL | 2.1767 mL | 4.3533 mL | 10.8833 mL | |
| 20 mM | 0.3265 mL | 1.6325 mL | 3.2650 mL | 8.1625 mL | |
| 25 mM | 0.2612 mL | 1.3060 mL | 2.6120 mL | 6.5300 mL | |
| 30 mM | 0.2177 mL | 1.0883 mL | 2.1767 mL | 5.4416 mL | |
| 40 mM | 0.1632 mL | 0.8162 mL | 1.6325 mL | 4.0812 mL | |
| 50 mM | 0.1306 mL | 0.6530 mL | 1.3060 mL | 3.2650 mL | |
| 60 mM | 0.1088 mL | 0.5442 mL | 1.0883 mL | 2.7208 mL | |
| 80 mM | 0.0816 mL | 0.4081 mL | 0.8162 mL | 2.0406 mL | |
| 100 mM | 0.0653 mL | 0.3265 mL | 0.6530 mL | 1.6325 mL |
4-Aminosalicylic acid Related Classifications
HY-I0447 Related Classifications
Powered by Bioz